Zhejiang Hisoar Pharmaceutical Co., Ltd.

Total Valuation

Zhejiang Hisoar Pharmaceutical Co., Ltd. carries a market capitalization of 8.77B, placing it among publicly traded companies globally. Its enterprise value stands at 4.85B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Zhejiang Hisoar Pharmaceutical Co., Ltd. currently has 1.62B shares outstanding.

Valuation Ratios

The price-to-sales ratio is 2.78, and the price-to-book ratio stands at 2.41.

Enterprise Valuation

On an enterprise value basis, Zhejiang Hisoar Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 1,205.63 and an EV/FCF ratio of 31.25. The EV/Sales ratio of 2.66 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 1,205.63 provides insight into valuation relative to core operating earnings.

Financial Position

Zhejiang Hisoar Pharmaceutical Co., Ltd. maintains a current ratio of 1.33, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 31.00, indicating elevated leverage, while an interest coverage ratio of 0.16 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Zhejiang Hisoar Pharmaceutical Co., Ltd. has paid 3.90M in income taxes, reflecting an effective tax rate of 69.65.

Stock Price Statistics

Zhejiang Hisoar Pharmaceutical Co., Ltd.'s stock has declined approximately -9.81697% over the past 52 weeks. The 50-day moving average sits at 5.74, while the 200-day moving average is 6.39.

Income Statement

Over the trailing twelve months, Zhejiang Hisoar Pharmaceutical Co., Ltd. generated 1.82B in revenue and converted that into -354.28M in net income, yielding earnings per share of -0.39. EBITDA reached 4.02M, while operating income came in at 4.02M.

Balance Sheet

Zhejiang Hisoar Pharmaceutical Co., Ltd. holds 1.81B in cash and equivalents against 1.59B in total debt, resulting in a net debt position of -204.55M. Total book value stands at 2.11B, with working capital of 802.33M providing operational flexibility.

Cash Flow

After subtracting -129.81M in capital expenditures, free cash flow totaled -129.81M - equivalent to -0.14 per share.

Margins

Zhejiang Hisoar Pharmaceutical Co., Ltd. operates with a gross margin of 25.64, reflecting its pricing power and cost economics. The operating margin of 0.22 and net profit margin of -19.41 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -6.55 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Zhejiang Hisoar Pharmaceutical Co., Ltd.'s most recent stock split took place on March 1, 2016 with a 1:2 split ratio.

Scores

Zhejiang Hisoar Pharmaceutical Co., Ltd. posts an Altman Z-Score of 1.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.